A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Pelacarsen (Primary) ; Inclisiran
- Indications Cerebrovascular disorders; Coronary disorders; Peripheral arterial disorders
- Focus Registrational; Therapeutic Use
- Acronyms ADD-VANTAGE
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 13 Feb 2025 New trial record